

# FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* <b>Kelderman Kim</b>			2. Issuer Name and Ticker or Trading Symbol <b>BIO-TECHNE Corp [TECH]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <b>Pres. Diagnostics &amp; Genom</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>05/01/2021</b>					
614 MCKINLEY PLACE NE								
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
MINNEAPOLIS, MN 55413								
(City) (State) (Zip)			<b>Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned</b>					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/01/2021		M		1,667	A	(1)	2,512	D	
Common Stock	05/01/2021		F		856	D	\$ 427.49	1,656	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
*(e.g., puts, calls, warrants, options, convertible securities)*


1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Title
Restricted Stock Units	(1)	05/01/2021		M		1,667	(2)	(2)	Common Stock	1,667	\$ 0	0	D	
Stock Options (Right to Buy)	\$ 150.78						(3)	05/01/2025	Common Stock	2,652		2,652	D	
Stock Options (Right to Buy)	\$ 150.78						(4)	05/01/2025	Common Stock	7,348		7,348	D	
Restricted Stock Units	(1)						(5)	(5)	Common Stock	1,691		1,691	D	
Stock Options (Right to Buy)	\$ 177.32						(6)	08/08/2025	Common Stock	12,044		12,044	D	
Stock Options (Right to Buy)	\$ 177.32						(5)	08/08/2025	Common Stock	9,033		9,033	D	

Restricted Stock Units	(1)						(7)	(7)	Common Stock	2,363		2,363	D
Stock Options (Right to Buy)	\$ 190.41						(7)	08/07/2026	Common Stock	11,961		11,961	D
Stock Options (Right to Buy)	\$ 190.41						(8)	08/07/2026	Common Stock	15,948		15,948	D
Restricted Stock Units	(1)						(9)	(9)	Common Stock	2,015		2,015	D
Stock Options (Right to Buy)	\$ 267.87						(9)	08/05/2027	Common Stock	8,991		8,991	D
Stock Options (Right to Buy)	\$ 267.87						(10)	08/05/2027	Common Stock	11,988		11,988	D
Stock Options (Right to Buy)	\$ 267.87						(11)	08/05/2027	Common Stock	8,325		8,325	D
Stock Options (Right to Buy)	\$ 267.87						(12)	08/05/2027	Common Stock	8,325		8,325	D

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kelderman Kim 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413			Pres. Diagnostics & Genom	

## Signatures

/s/ Brenda S. Furlow as Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.		05/04/2021
		Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) 1,667 restricted stock units vest on 5/1/2021.
- (3) Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
- (4) Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.
- (5) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.
- (7) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (8) Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.
- (9) Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (10) Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
- (11) Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
- (12) Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

